How to use mTOR inhibitors in children

Area of Science:

• Pediatric Pharmacology
• Oncology
• Genetics

Background:

• Mammalian target of rapamycin (mTOR) inhibitors like sirolimus and everolimus are increasingly used in pediatric care.
• Conditions such as tuberous sclerosis and vascular malformations are expanding indications for mTOR inhibitor treatment.
• Paediatricians and pharmacists require clear guidance on managing these complex therapies.

Purpose of the Study:

• To provide a practical guide for healthcare professionals initiating mTOR inhibitor treatment in children.
• To outline essential information regarding potential side effects and family counseling.
• To detail recommended monitoring strategies for pediatric patients on mTOR inhibitors.

Main Methods:

• This practice pointer summarizes current evidence and clinical recommendations.
• It focuses on practical steps for treatment initiation, side effect management, and ongoing monitoring.
• The content is tailored for paediatricians and pharmacists involved in pediatric care.

Main Results:

• Key considerations before starting mTOR inhibitors include patient selection and baseline assessments.
• Common and serious side effects, such as stomatitis, rash, and metabolic changes, are discussed.
• Regular monitoring of blood counts, metabolic parameters, and treatment-specific toxicities is crucial.

Conclusions:

• Effective management of pediatric patients on mTOR inhibitors requires a multidisciplinary approach.
• Proactive discussion of side effects and vigilant monitoring are essential for optimizing outcomes.
• This guidance aims to support safe and effective use of mTOR inhibitors in pediatric practice.